Lumos Gains Early Commercial Traction for FebriDx in the U.S.
Lumos Diagnostics Holding Limited (ASX: LDX) has reported encouraging progress in the early-stage rollout of its FebriDx rapid diagnostic test in the United States after securing FDA CLIA waiver approval earlier this year. Initial reimbursement outcomes have been positive, with a high percentage of claims successfully paid and average reimbursement levels exceeding standard Medicare pricing benchmarks.
The company has already introduced FebriDx into dozens of urgent care clinics through WellStreet, while additional healthcare operators are currently assessing and implementing the product through pilot programs. Lumos is also expanding discussions with other urgent care providers as it builds momentum ahead of future flu seasons.
Management believes these early results demonstrate growing acceptance of FebriDx® within routine clinical settings, particularly where healthcare providers require efficient testing solutions combined with reliable reimbursement pathways. The company remains focused on strengthening customer adoption, improving workflow integration, and expanding its commercial presence across the broader U.S. healthcare market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Lumos Gains Early Commercial Traction for FebriDx in the U.S.
Lumos Diagnostics Holding Limited (ASX: LDX) has reported encouraging progress in the early-stage rollout of its FebriDx rapid diagnostic test in the United States after securing FDA CLIA waiver approval earlier this year. Initial reimbursement outcomes have been positive, with a high percentage of claims successfully paid and average reimbursement levels exceeding standard Medicare pricing benchmarks.
The company has already introduced FebriDx into dozens of urgent care clinics through WellStreet, while additional healthcare operators are currently assessing and implementing the product through pilot programs. Lumos is also expanding discussions with other urgent care providers as it builds momentum ahead of future flu seasons.
Management believes these early results demonstrate growing acceptance of FebriDx® within routine clinical settings, particularly where healthcare providers require efficient testing solutions combined with reliable reimbursement pathways. The company remains focused on strengthening customer adoption, improving workflow integration, and expanding its commercial presence across the broader U.S. healthcare market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au